We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Subcutaneous Infusion Pump Boosts ‘On’ Time in Parkinson’s Patients
Subcutaneous Infusion Pump Boosts ‘On’ Time in Parkinson’s Patients
AbbVie’s investigational subcutaneous ABBV-951( foslevodopa/foscarbidopa) delivery system racked up impressive numbers in a pivotal 12-week phase 3 study for patients with advanced Parkinson’s disease.